Analyst, Jefferies Japan
Appears in 1 story
Framing upside as meaningfully larger if zasocitinib expands beyond psoriasis into broader immune indications
Psoriasis has been an injectable kingdom for years: shots that work great, pills that usually don't. Takeda's once-daily TYK2 pill zasocitinib just cleared Phase 3 topline hurdles—and by the next session investors responded, sending Takeda shares up as much as 4.3% in early Tokyo trading (a seven-month-high intraday jump).
Updated May 15
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
